Guidelines for regulating the non-scheduled formulations

1898. SHRI ANANT RAM JAISWAL Will the PRIME MINISTER be pleased to refer to the reply to the Unstarred Question 390 given in Rajya Sabha on the 25th February, 1993 and state:

(a) whether it is a fact that the prices up by over 100 per cent after the announcement of DPCO, 1987 and the answer to above question and what are their prices now;

(b) whether it is a fact that even after of five medicines referred to gone monitoring they contain 300 per cent mark up and on the basis of Form 2A mark up and prices have not been reduced; and

(c) whether there are any guidelines basis and parameters for regulating the prices of non-scheduled formulations and if so, what are the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) Yes, Sir. Between the date of commencement of DPCO, 87 and the 25-2-93, the prices of the five medicines have recorded an increase of more than 100 per cent. The current prices of these medicines are given below:

1. Betaloc Inj. 5×5 ml.	12.25
2. Calcium Sandoz Syp.	210 ml.29 41
3. Pethidine Inj. 10 Amp.	33.00
4. Corbetta Tabs. 10 mg. 10's	3.53
5. Pondrax 20 mg. 10×10	265.48
-do- 60 mg. 10's	81.75

(b) No, Sir. Mark up is not of the order of 300 per cent.

(c) Monitoring of prices of non-scheduled formulations is done to the extent possible, keeping in view the provisions of DPCO, '87.

Identification of recovery cases

1899. SHRI H. HANUMANTHAPPA: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1234 given in the Rajya Sabha on 4.3.93 and state:

(a) whether it is a fact that except for court orders the present team headed by Development Commissioner (PI) has failed to recover any amount into DPEA during the last two years;

(b) whether it is a fact that even the liabilities during the past two years in the identified cases have not been worked out; and

(c) what steps are proposed to be taken to inquire into the matter and fixing of responsibilities?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) to (c) It is not a fact that no amount has been recovered into the Drug Price Equalisation Account during the last two years. The liabilihowever, been challenged in various ties that have been determined have, courts and have also been disputed by the companies. It has, however, been possible to recover Rs. 191.78 lakhs in the last two years.

Decline in product units of IDPL

1900. SHRI H. HANUMANTHAPPA: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred question 1983 given in the Rajya Sabha on 1173.93 and state:

(a) whether capital output ratio at original cost has fallen in IDPL and this position has became irretrievable;

(b) what are the cumulative losses of IDPL so far and what is the expected loss during 1993-94;

(c) whether the option of disposing of the undertaking is being considered in order to ensure that it is revamped and becomes productive; and

(d) whether its sales in terms of product units is also declining and if so, what has been the decline during the past three years?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) No, Sir.

(b) The estimated accumulated losses of IDPL as on 31.3.93 are Rs. 623 crores. The company has, in compliance with the provisions of the Sick Industrial Companies (Special Provisions) Act, 1985, made a reference to the Board for Industrial and Financial Reconstruction (BIFR). A Rehabilitation Plan is under preparation. It would be premature to indicate the loss of 1993-94 at this stage.

(c) There is no such proposal under consideration at present.

(d) The details in respect of sales of major key bulk drugs during the last three years are given in the Statement enclosed. (*See* below) The statement shows mixed trends with the sales of some items going up and of the others coming down.

Statement

Sales of major key bulk drugs during 1990-91, 1991-92 *and* 1992-93.

PRODUCTS	UNIT	1990-91	1991-92	1992-93
Penicillion	MMU	270.5	243.7	381.2
Tetracycline	MT	61.8	27.5	15.0
Oxytetracycline	MT	41.5	60.9	72.9
Vitamin B1	MT	67.7	76.6	55.3
Vitamin B2	MT	21.5	18.2	19.8
Folic Acid	MT	3.5	4.0	6.41
Niacinamide	MT	44.9	83.1	91.3
Acetazolamide	MT	6.0	3.2	7.5
Barbital Sodium	MT	..	0.8	5.51

Controlling the prices of drugs

1901. SHRMATI KAILASHPATI: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1986 given in the Rajya Sabha on 11-3-93 and state:

(a) whether it is a fact that the material cost for Cifran, Calmpose, Evion, Daonil and trexyl is highly inbated and that Government have not scrutinised these costs;

(b) whether Government would ensure the sale of Trexyl at Rs. 2.05 per tablet when it is a single anti-hretamine and heavy foreign exchange is being passed outside the country; and

(c) what steps have been taken to conduct enquiry into the affairs of producers of Trexyl?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) to (c) As already stated in answer to question No. 1986 dated 11.3.93, all these formulations are outside price control. If there is an exorbitant increase in the prices of the non-scheduled formulation, over the earlier